Carvykti genetically modified autologous T cells for infusion Images
Generic Name: ciltacabtagene autoleucel
This medication has been identified as Carvykti genetically modified autologous T cells for infusion. It is supplied by Janssen Biotech, Inc.
Carvykti is used in the treatment of Multiple Myeloma and belongs to the drug class miscellaneous antineoplastics. Carvykti genetically modified autologous T cells for infusion is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Carvykti
- Generic Name
- ciltacabtagene autoleucel
- Strength
- genetically modified autologous T cells for infusion
- Availability
- Prescription only
- Drug Class
- Miscellaneous antineoplastics
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Janssen Biotech, Inc.
- National Drug Code (NDC)
- 57894-0111
More about Carvykti (ciltacabtagene autoleucel)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
